05.17.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
05.08.18 Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
